SIMCERE PHARMA (02096) announced that pursuant to a shareholders' resolution passed at the annual general meeting held on June 13, 2025, the company's directors have been granted general authorization to repurchase up to 247 million company shares, representing 10% of the total issued shares as of June 13, 2025. On August 21, 2025, the board of directors resolved to exercise the repurchase authorization to repurchase shares on the open market at appropriate times for a total amount not exceeding RMB 500 million. The board believes that repurchasing shares at this stage demonstrates the company's confidence in its business prospects and will ultimately benefit the company and create value for shareholders. Additionally, the board considers that the company currently possesses sufficient financial resources to conduct the proposed share repurchase while maintaining a stable financial position.